Please assess the completion status of the following clinical trial:

Trial Title: Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject meets any of the following criteria and with sUA ≤10.0 mg/dL:~  1. sUA level of \>7.0 mg/dL at 7 days prior to baseline with gout;~ 2. sUA level of ≥8.0 mg/dL at 7 days prior to baseline without gout but with complications (hypertension, ischemic heart disease, diabetes, metabolic syndrome);~ 3. sUA level of ≥9.0 mg/dL at 7 days prior to baseline without gout and complications.~Exclusion Criteria:~* Subject with an acute gout flare that has not resolved at least 14 days prior to the baseline visit.~* Subject has a history or suspicion of kidney stones.~* Subject has an estimated creatinine clearance \<60 mL/min calculated by the Cockcroft Gault formula~* Subject is receiving strong or moderate CYP3A inhibitors

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- RDEA3170 1 (Type: EXPERIMENTAL): RDEA3170 5mg followed by RDEA3170 7.5mg
- RDEA3170 2 (Type: EXPERIMENTAL): RDEA3170 10mg followed by RDEA3170 12.5mg
- RDEA3170 3 (Type: EXPERIMENTAL): RDEA3170 12.5mg followed by RDEA3170 15mg
- RDEA3170 4 (Type: PLACEBO_COMPARATOR): RDEA3170 Placebo
- Allopurinol (Type: OTHER): Allopurinol 200mg

Based on this trial design, predict the completion outcome and termination type (if applicable).